Payers, Hospitals Loom Large In China Drug Pricing Proposal
This article was originally published in PharmAsia News
First it was low-cost drugs, now all drugs are set to have their retail price ceilings lifted as China vows to allow a bigger role for market forces in the pricing of medicines. However, companies will have to negotiate with the payer and individual hospitals to benefit from the proposal.
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.